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Intramuscular Botulinum Toxin-A Reduces
Hemiplegic Shoulder Pain
A Randomized, Double-Blind, Comparative Study Versus
Intraarticular Triamcinolone Acetonide
Jae-Young Lim, MD, PhD; Jae-Hyeon Koh, MD, MS; Nam-Jong Paik, MD, PhD
Background and Purpose—Shoulder pain is frequent after stroke and interferes with the rehabilitative process and
outcome. However, treatments used for hemiplegic shoulder pain are limited and largely ineffective. This prospective,
randomized, double-blind controlled study was conducted to compare the efficacies of botulinum toxin type A
(BoNT-A) and triamcinolone acetonide (TA) on hemiplegic shoulder pain and their effects on arm function in patients
with stroke.
Methods—Twenty-nine hemiplegic stroke patients with shoulder pain (duration 24 months, pain on numeric rating scale
6/10) were randomized into 2 groups. One group received intramuscular injections of BoNT-A (BOTOX 100 U total)
during one session to the infraspinatus, pectoralis and subscapularis muscles in conjunction with an intraarticular
injection of normal saline to painful shoulder joint, whereas the other group received an intraarticular injection of TA
(40 mg) and an intramuscular injection of normal saline to the same muscles. Outcome measures were pain (measured
using a numeric rating scale), physician’s global rating scale, shoulder range of motion (ROM) in 4 directions, arm
function measured using Fugl-Meyer score, and spasticity measured using the modified Ashworth scale. Measurements
were made at baseline and 2, 6, and 12 weeks after injection.
Results—At 12 weeks after treatment mean decrease in pain was 4.2 in the BoNT-A–treated group versus 2.5 in the
TA-treated group (P0.051), and improvements in overall ROM were 82.9o versus 51.8o in these groups (P0.059),
showing a strong trend toward there being less pain and better ROM among those treated with BoNT-A than with TA.
However, no significant differences were observed between the 2 groups in terms of improvement in physician global
rating, Fugl-Meyer score or modified Ashworth scales. No adverse effect was observed in either group.
Conclusions—Results from this study suggest that injection of BoNT-A into selected muscles of the shoulder girdle might
provide more pain relief and ROM improvement than intraarticular steroid in patients with hemiplegic shoulder pain.
A larger clinical trial needs to be undertaken to confirm the benefits of this approach. (Stroke. 2008;39:126-131.)
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Shoulder pain is one of the most frequent complications ofhemiplegia, and occurs in 20% to 70% of stroke patients.
Moreover, it can interfere with the rehabilitative process and
has been associated with poorer outcomes and prolonged
hospital stays.1–9 A variety of factors may be responsible for
shoulder pain after stroke, eg, joint pathology, adhesive
capsulitis, subluxation of the head of the humerus, injury to
rotator cuff tendons, spasticity of surrounding muscles, cen-
tral poststroke pain, and complex regional pain syn-
drome.10–13 However, the etiology of hemiplegic shoulder
pain (HSP) remains uncertain.
With regard to treatment, nothing has yet been proven
effective, although different treatment methods such as phys-
ical therapy,12 functional electrical stimulation,14,15 and intra-
articular steroid injection16,17 are being applied. In clinical
practice, physicians frequently treat HSP using steroid injec-
tions,17 although their effects remain controversial.16–18
Botulinum toxin type A (BoNT-A) has been widely used to
treat spasticity and other forms of muscle overactivity,19–24
and recently has been used to treat chronic pain, such as,
myofascial pain, low back pain, lateral epicondylitis, various
types of headaches, and neuropathic pain.25–34 The mecha-
nism of pain reduction by BoNT-A may include a muscle
relaxant effect35 and the inhibition of neurotransmitter release
by sensory neurons.36–44
Given that the suggested pain relieving mechanisms of
BoNT-A cover the possible etiologies of HSP, we considered
that BoNT-A might be effective for treating HSP. In this
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study, we conducted a randomized clinical trial to compare
the effects of intramuscular BoNT-A with those of intraartic-
ular steroid on HSP and hemiplegic arm function in stroke
patients. We hypothesized that BoNT-A injected into selected
muscles in the region of the hemiplegic shoulder joint would
elicit more significant pain reduction and range of motion




Twenty-nine patients with hemiplegic shoulder pain aged 18 to 78
years were recruited for this study. The inclusion criteria were: (1)
hemiplegia in an arm after stroke (maximum time interval between
BoNT-A treatment and stroke 24 months and duration of pain 12
months), (2) a pain level in the hemiplegic shoulder of 6 (on a
numeric scale of 0 to 10) as rated by the patient during passive ROM
during at least 2 of 3 visits before enrollment, (3) limitation of
passive external rotation of the hemiplegic shoulder of at least 20°
compared with the unaffected side. Exclusion criteria were: (1) an
intraarticular injection into the affected shoulder during the previous
6 months or use of systemic corticosteroids during the previous 4
months, (2) the presence of an other obvious explanation for the pain
(eg, fracture, radiculopathy), (3) prior surgery to either the shoulder
or neck region, (4) patient immobility involving confinement to bed
for 50% of daytime hours, (5) any medical condition that might
increase the risk to the subject with exposure to BoNT-A (eg,
diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotro-
phic lateral sclerosis, or any other disorder that might interfere with
neuromuscular function), (6) a known allergy or sensitivity to any
component of the medication, (7) evidence of recent alcohol or drug
abuse or severe depression, (8) the presence of an unstable medical
condition or a known uncontrolled systemic disease, (9) concurrent
participation in another drug or device study or participation in such
a study during the 30 days before enrollment, (10) prior treatment
with BoNT-A, (11) the use of aminoglycoside antibiotics, curare-like
agents, or any other agent that might interfere with neuromuscular
function, and finally (12) any condition or situation that might place
the subject at significant risk. Subjects were recruited from a single
center, both from inpatients and outpatient clinic, between May 2004
and February 2006.
This study protocol was approved by the institutional review
board, and all participants provided signed, written, informed con-
sent. The study was conducted in accordance with regulatory
standards of Good Clinical Practice and the Declaration of
Helsinki.45
Interventions
The present study was a prospective randomized, double-blind,
clinical trial which compared intramuscular BoNT-A and intraartic-
ular triamcinolone acetonide (TA). Patients were randomized into 2
groups (the BoNT-A and TA groups) using a stratified randomiza-
tion procedure with permuted block size of 4 using a computer that
balanced ages (65 or 65 years) and sexes (male or female) in the
2 groups before the trial. For the treatment allocation, numbered
sealed envelopes were used.
Intramuscular BoNT–A injections and intraarticular saline injec-
tion were administered to the BoNT-A group, whereas intramuscular
saline injections and intraarticular TA injections were administered
to the TA group. BoNT-A (Botox, Allergen) was injected into the
infraspinatus, subscapularis and pectoralis muscles, which are be-
lieved to be responsible for shoulder pain46–48 using 27 gauge
monopolar needle under electromyographic guidance. One vial of
Botox (100 U) was reconstituted with 4.0 mL of saline at a
concentration of 25 U/mL. A dose of 100 U of Botox was selected
as being both optimal and cost-effective based on our open-labeled
pilot study, where we compared the effects of Botox at 100 U and
150 U on HSP over 6 weeks (unpublished data).
Each muscle was injected at 2 points at least and no one injection
point received more than 25 U. The maximum total dose in any one
muscle was 50 U and a maximum total dose per patient was 100 U.
The control group received intraarticular injections of TA (40 mg)
and 4.0 mL injections of intramuscular saline to the infraspinatus,
subscapularis and pectoralis muscles. All patients received a stan-
dard course of physiotherapy during the 6-week period after injection
with a minimum of 2 visits per week by a physical therapist blinded
to group. In addition, all patients were given a standard brochure
describing self-ROM exercise. Randomization codes were kept by
one physician, and injection materials were prepared by this physi-
cian out of sight of patients. Syringes were sealed with plaster before
injection to blind patients. Injection and evaluation were performed
by separate physicians. One physician evaluated the outcome mea-
sures, and he was blinded to group allocation throughout the study.
Therefore, the patients and all other people involved, except for the
injecting physicians, were blinded for the type of treatment.
Outcome Measures
The primary outcome measures were pain measured using a numeric
rating scale49,50 (NRS on a scale of 010; where 0no pain and
10highest pain level) during passive ROM of the shoulder in 4
planes (forward flexion, abduction, external and internal rotation), a
physician global rating scale51,52 (range 0 – 4: 0no change;
1slight improvement, but below the defined therapeutic goal;
2attained the defined therapeutic goal; 3improvement slightly
exceeding the defined therapeutic goal; 4improvement clearly
exceeding the defined therapeutic goal), and the passive ROM of the
shoulder in four planes using goniometry: forward flexion, abduc-
tion, external rotation, and internal rotation. All ROMs were mea-
sured in seated position.
Secondary outcome measures were arm function measured using
Fugl-Meyer scores53 (range 0–66, 0no function; 66normal
function), and spasticity measured at the external rotator muscles of
the shoulder using the modified Ashworth scale54 (range 0–5, 0no
spasticity; 5joint is rigid in flexion or extension). Adverse effects
were monitored throughout the study. Measurements were made at
baseline and 2, 6, and 12 weeks after injection by a blind evaluator.
Statistical Analysis
We estimated that a sample size of 12.3 per group (14.5 considering
a 15% follow-up loss) were needed to achieve 80% statistical power
to detect a 2.0 difference in pain scores between the treatment groups
at a statistical significance level of 0.05.
In this study, subjects that provided baseline and at least 1
posttreatment measurement constituted the Intention-to-Treat (ITT)
population, whereas those completed all tests from baseline to the
12-week follow-up constituted the Per Protocol (PP) population. For
the ITT population, outcome measurements were analyzed using the
last observation carried forward (LOCF) method.55
After normal distributions were assessed using the Kolmogorov-
Smirnov test, we used repeated measures ANOVA (ANOVARM) with
“GROUP” (BoNT-A versus TA) as the between-subject factor and
“TIME” (baseline and 2, 6, and 12 weeks postinjection) as the
within-subject factor to compare the effects of GROUP and TIME on
HSP. Conditioned on significant F-values (P0.05), post hoc anal-
yses were conducted and corrected for multiple comparisons with
Tukey tests.
Results
Four of the initial 29 participants (2 from the BoNT-A group,
2 from the TA group) were lost to follow-up because of
admission to other hospitals (n3) or poor general condition
(n1). After first follow-up (2 weeks after the injection), 3
other patients also dropped out (1 patient in week 6 and 2
during week 12, Figure 1). No side effects were observed
in either group over the 12-week follow-up period. At
baseline, no significant differences were detected between
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the two groups in terms of age, sex, etiology, or pain
duration (Table 1).
Intention-To-Treatment Analysis Using the
LOCF Method
Twenty-five patients who were followed-up at least once
were included in the ITT analysis (Table 2).
At baseline, pain intensity was comparable in the 2 groups
(7.90.3, MeanSE in the BoNT-A group and 7.60.5
in the TA group, P0.690 by t test). ANOVARM showed
a significant effect of TIMEbaseline, LOCF [F(1,23)61.1;
P0.001], but not of GROUPBoNT-A, TA [F(1,23)1.2;
P0.287] without a significant interaction TIMEbaseline, LOCF X
GROUPBoNT-A, TA [F(1,23)4.3; P0.051]. We performed
post hoc testing because the interaction approached a statis-
tical significance, and it showed no differences in pain
reduction at LOCF (P0.100). However, there was a strong
tendency toward mean decrease in pain intensity being more
prominent in the BoNT-A group (4.20.4) than the TA group
(2.50.8) with independent samples t test (P0.051).
However ANOVARM revealed no significant effect of
TIMEbaseline, LOCF [F(1,23)1.2; P0.278] and GROUPBoNT-A, TA
[F(1,23)0.3; P0.573] without a interaction [F(1,23)0.1;
P0.928] in physician global rating scale, indicating there
was no detectable differential effect of BoNT-A versus TA on
the physician’s rating.
ANOVARM applied to total ROM revealed a significant
effect of TIMEbaseline, LOCF [F(1,23)74.2; P0.001], but not of
GROUPBoNT-A, TA [F(1,23)2.8; P0.106] without a signifi-
cant interaction [F(1,23)4.0; P0.059], indicating that
ROM was improved in both groups. However, total ROM
was more reduced in the BoNT-A group (82.99.4o) than the
TA group (51.812.9o) with t test (P0.059), although
baseline values were not comparable at baseline (270.79.9o
in the BoNT-A group versus 313.213.6o in the TA group,
P0.016 by t test).
ANOVARM applied to each 4 planes (forward flexion,
abduction, external rotation, and internal rotation) showed
similar effects but internal rotation, which showed a signifi-
cant GROUPBoNT-A, TA effect (Table 2).
Arm function as determined using Fugl-Meyer scores was
comparable in the 2 groups at baseline (33.74.8 in the
BoNT-A group and 23.87.5 in the TA group, P0.260 by
t test). ANOVARM showed a significant effect of TIMEbaseline, LOCF
[F(1,23)14.2; P0.001], but not of GROUPBoNT-A, TA
[F(1,23)2.1; P0.164] without a significant interaction
[F(1,23)1.7; P0.210], reflecting both groups improved in
arm function.
Regarding Modified Ashworth scale, ANOVARM revealed
no significant effect of TIMEbaseline, LOCF [F(1,23)1.5;
P0.227], GROUPBoNT-A, TA [F(1,23)3.4; P0.079] or inter-
action [F(1,23)0.2; P0.702].
Per Protocol Analysis
Twenty-two patients (11 from the BoNT-A group and 11
from the TA group) who completed final follow-up evalua-
tions were included in the PP analysis.
Although pain intensity was comparable in the 2 groups at
baseline (P0.737 by t test), mean decrease in pain intensity
was greater in the BoNT-A group (7.50.3 at baseline to
3.20.5 at 12 weeks postinjection) than in the TA group
(from 7.60.5 to 5.20.8, P0.064 by t test). ANOVARM
applied to pain scales showed a significant effect of
TIMEbaseline, 2, 6, and 12 weeks [F(3,60)29.8; P0.001], but not of
GROUPBoNT-A, TA [F(1,20)1.3; P0.256], without a signifi-
cant interaction [F(3,60)2.8; P0.050]. Post hoc testing
showed no statistical differences between the two groups over
time (P0.05, Figure 2).
For the net changes in physician global rating scales,
ANOVARM revealed no TIME2, 6, 12 weeks [F(2,40)1.8;
P0.171], GROUPBoNT-A, TA [F(1,20)1.0; P0.334], or in-
teraction effect [F(2,40)0.4; P0.662].
The improvement in shoulder ROM (sum of 4 directions)
was greater in the BoNT-A group than in the TA group
(91.08.7o versus 51.812.9o, P0.021 by t test).
ANOVARM applied to total ROM revealed a significant
effect of TIMEbaseline, 2, 6, 12 weeks [F(3,60)54.8; P0.001], but
not of GROUPBoNT-A, TA [F(3,20)0.9; P0.348], with a
significant interaction [F(3,60)4.2; P0.009]. However,
post hoc testing did not show any statistical differences
between the 2 groups over time (P0.05, Figure 3), suggest-
ing that the greater improvement in shoulder ROM in the
BoNT-A group than in the TA group might be caused by
differences in baseline value between 2 groups (279.110.4o
in the BoNT-A group versus 313.213.6o in the TA group,
P0.060 by t test).
ANOVARM applied to Fugl-Meyer score showed a signif-
icant effect of TIMEbaseline, 2, 6, 12 weeks [F(3,60)10.7; P0.000],





Age, y 64.82.1 57.13.6 0.079




Involved side, right/left 6/10 3/10 0.404
Time since onset, days 230.453.8 299.573.9 0.446


















Admission at other hospital  2
Discontinued (N=1)
Follow Up Loss 1
Discontinued (N=2)
Follow Up Loss 1
Discontinued (N=2)
Admission at other hospital 1
Poor general condition 1
Figure 1. Flow chart of the study.
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but not of GROUPBoNT-A, TA [F(1,20)2.5; P0.133], in the
absence of a significant interaction [F(3,60)1.9; P0.138]
(Figure 4), and spasticity scores were comparable over
TIMEbaseline, 2, 6, 12 weeks [F(3,60)0.9, P0.469] and GROUPBoNT-A, TA
[F(1,20)1.7, P0.203] without a significant interaction
[F(3,60)0.2; P0.906].
Discussion
The main finding of this double-blind randomized study was
that injections of BoNT-A into shoulder girdle muscles
showed a strong trend to reduce HSP and improve shoulder
ROM more so than intraarticular steroid injections. Further-
more, this positive effect of BoNT-A treatment over steroid
was more evident at 12 weeks postinjection, which suggests
that BoNT-A might have a longer lasting effect than steroid.
Treatments were well tolerated and no adverse event was
observed in any subject.
Recently, Yelnik et al48 reported that intramuscular injec-
tions of BoNT-A into subscapularis muscles elicited more
significant pain relief and ROM improvement than a placebo
at 4 weeks postinjection in a double-blind, randomized,
placebo-controlled study, which concurs with the results of
the present study. In our study we used an active drug rather
than placebo as a control and followed the outcome measures
longer than Yelnik et al’s study, which provided more evident
effect of BoNT-A on HSP. We think that it is possible that
even better or longer results could have been achieved using
a higher dose because the beneficial effects of BoNT-A over
steroid were prominent after 12 weeks postinjection in the
present study, which needs further exploration.
Given the fact that the causes of HSP are uncertain and
that an effective treatment has yet to be established, we
decided to treat HSP using BoNT-A injections. In this
study, we selected intraarticular steroid injection as a control
therapy, because this therapy is frequently applied in the
clinical setting and one survey showed that clinicians be-
lieved in its effectiveness.56
We believe that the possible mechanisms of improved
hemiplegic shoulder pain after BoNT-A injection could be
associated with the antinociceptive effect of BoNT-A. Al-
though no direct association between BoNT-A and spasticity
was found during the present study, the muscle relaxing or
tone reducing effects of BoNT-A might also have contributed
to pain reduction. We believe that the limited observed effect
of BoNT-A on spasticity was probably because of the fact
that we recruited patients with mild to moderate degrees of
spasticity, which concurs with the findings that BoNT-A did
























Figure 2. Improvement in numeric pain rating scale during the
study (PP analysis). ANOVARM revealed a significant effect of
TIME [F(3,60)29.8; P0.001], but not of GROUP [F(1,20)
1.3; P0.256], without a significant interaction [F(3,60)2.8;
P0.050]. Post hoc testing showed no statistical differences
between the 2 groups over time (P0.05).












 Pain, numeric rating scale 4.20.4 2.50.8 0.001 0.287 0.051
 Physician global rating scale 0.20.2 0.20.3 0.278 0.573 0.928
 Passive ROM of shoulder,o 82.99.4 51.812.9 0.001 0.106 0.059
Flexion 21.54.3 13.24.6 0.001 0.150 0.204
Abduction 22.94.1 17.34.3 0.001 0.569 0.362
External rotation 21.13.4 13.25.8 0.001 0.334 0.231
Internal rotation 17.52.6 8.24.2 0.001 0.010 0.062
 Fugl-Meyer score 10.02.2 4.93.5 0.001 0.164 0.210
 Modified Ashworth scale 0.10.1 0.30.4 0.227 0.079 0.702






























Figure 3. Improvement in shoulder passive range of motion
(ROM) during the study (PP analysis). ANOVARM revealed a
significant effect of TIME [F(3,60)54.8; P0.001], but not of
GROUP [F(3,20)0.9; P0.348], with a significant interaction
[F(3,60)4.2; P0.009]. Post hoc testing did not show any sta-
tistical differences between the 2 groups over time (P0.05).
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TA. It is also possible that the small population size may have
contributed to this negative effect. Our sample size estimation
was based on pain improvement rather than spasticity or arm
function, and the sample size required to detect significant
spasticity or arm functional improvement changes would
have been larger.
The main limitation of the present study is its limited
sample size and follow-up loss. We think more than expected
follow-up loss (24.1% not 15% as estimated before trial)
might resulted in insufficient statistical power for ANOVARM
in the present study.
In conclusion, injections of BoNT-A into selected muscles
of the shoulder girdle provided more significant shoulder pain
relief and improved ROM of the shoulder but not arm
function versus the intraarticular injection of steroid. This
finding supports the idea that BoNT-A could be used as an
alternative treatment for hemiplegic shoulder pains that are
otherwise difficult to treat. A larger trial needs to be com-
menced to confirm the benefits of BoNT-A in HSP.
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